RE:RE:Re-HiringI have to disagree with you Infinity about the vaccine research being a long shot, on one point anyway. Yes Pfizer, Moderna and Astrazeneca were there first but all have had their issues and yes they all have the financial might and (corrupt) influence but in medicine doesn't 'better' still beat 'first'?
As you say TLT seems to have the side effect advantage so that gives hope. And I hate to say this but I don't think this will be the last virus we see, intentional or otherwise sadly, so their research isn't behind schedule.
This also applies to their ACT, there are treatments available now but we are all here because we think theirs is better. I might be naive but if I thought this was a long shot because big pharma would squash this I would have been out long ago.
Infinity wrote: tamarindo1 wrote: I notice that 'Director of Clinical Development" posn is no longer on the INDEED website.
I am looking forward to the 3rd quarter 2021 reports. My guess it would be out by end of October. Now that the new hires are in place, TLT is poised for an exciting growth period in terms of NMIBC positive test results, which should give a near term boost to the stock price when other investors start taking notice of the potential for PDT treatments..
The Vaccine research in my opinion would be a long shot. NML will most likely establish the efficacy of using PDT as a Vaccine and add another viable alternative to the current ones that are out in the market. Pfizer, Moderna and Astrazenaca will continue to grow simply becuase they got there first and they have solid financial muscle power to stay the course and also nfluence their Government's decisions. The major advantage that PDT has is that it has very minimal side effects that we know of. The lack of side effects could ultimately prove to be a winner!!!. Long shots do happen some times..